ArticleJournal of the American Medical Informatics Association : JAMIA2017
MeSHDD: Literature-based drug-drug similarity for drug repositioning.
Article in Journal of the American Medical Informatics Association : JAMIA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Large-scale Empirical Identification of Candidate Comparators for Pharmacoepidemiological Studies.Drug safety · 2025Article
- Predicting implicit concept embeddings for singular relationship discovery replication of closed literature-based discovery.Frontiers in research metrics and analytics · 2025Article
- Drug Repurposing: Insights into Current Advances and Future Applications.Current medicinal chemistry · 2025Review
- Analysis and identification of drug similarity through drug side effects and indications data.BMC medical informatics and decision making · 2023Article
- Drug-disease association prediction with literature based multi-feature fusion.Frontiers in pharmacology · 2023Article
- Article
- Computational Methods for Drug Repurposing.Advances in experimental medicine and biology · 2022Article
- Disulfiram in glioma: Literature review of drug repurposing.Frontiers in pharmacology · 2022Review
- HeTDR: Drug repositioning based on heterogeneous networks and text mining.Patterns (New York, N.Y.) · 2021Article
- Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents.Molecular diversity · 2021Article
- A multimodal deep learning-based drug repurposing approach for treatment of COVID-19.Molecular diversity · 2021Article
- Machine learning identifies candidates for drug repurposing in Alzheimer's disease.Nature communications · 2021Article
- Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.Viruses · 2020Review
- A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions.Journal of cheminformatics · 2020Review
- Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine.Database : the journal of biological databases and curation · 2020Article
- Creating Neuroscientific Knowledge Organization System Based on Word Representation and Agglomerative Clustering Algorithm.Frontiers in neuroinformatics · 2020Article
- Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases.Nature reviews. Rheumatology · 2020Review
- Meta-path Based Prioritization of Functional Drug Actions with Multi-Level Biological Networks.Scientific reports · 2019Article
- MAV-clic: management, analysis, and visualization of clinical data.JAMIA open · 2019Article
- Leveraging Population-Based Clinical Quantitative Phenotyping for Drug Repositioning.CPT: pharmacometrics & systems pharmacology · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveDrug repositioning is a promising methodology for reducing the cost and duration of the drug discovery pipeline. We sought to develop a computational repositioning method leveraging annotations in the literature, such as Medical Subject Heading (MeSH) terms.
methodsWe developed software to determine significantly co-occurring drug-MeSH term pairs and a method to estimate pair-wise literature-derived distances between drugs.
resultsWe found that literature-based drug-drug similarities predicted the number of shared indications across drug-drug pairs. Clustering drugs based on their similarity revealed both known and novel drug indications. We demonstrate the utility of our approach by generating repositioning hypotheses for the commonly used diabetes drug metformin.
conclusionOur study demonstrates that literature-derived similarity is useful for identifying potential repositioning opportunities. We provided open-source code and deployed a free-to-use, interactive application to explore our database of similarity-based drug clusters (available at http://apps.chiragjpgroup.org/MeSHDD/ ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.